Compare OPAD & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | PHIO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.1M |
| IPO Year | 2020 | 2011 |
| Metric | OPAD | PHIO |
|---|---|---|
| Price | $1.35 | $0.65 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.25 | N/A |
| AVG Volume (30 Days) | 32.1K | ★ 53.7K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $567,812,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.70 |
| 52 Week High | $6.09 | $1.88 |
| Indicator | OPAD | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 17.59 | 27.10 |
| Support Level | $0.63 | N/A |
| Resistance Level | $5.51 | $1.12 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 3.36 | 5.14 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.